Why Reproductive Harm Is Plausible but Not Yet Proven in People
Reproductive health is a useful stress test for claims about microplastics and nanoplastics because the evidence reaches from human semen, urine, placenta, and amniotic fluid to detailed experiments on reproductive cells and animals. This chapter follows that path without treating the ends as equivalent. The aim is to understand what human reproductive samples show, why the laboratory mechanisms are credible, and where the evidence still stops short of proving injury in people.
What human reproductive samples can show
The human review included seven studies of the genitourinary or reproductive system: two focused on males and five on females. They did not all ask the same question or sample the same compartment. Some measured particles in semen or urine. Others examined placenta, amniotic fluid, uterine tissue, fibroids, myometrium, prostate tissue, or cervical-cancer samples. That distinction matters because a particle in urine may reflect excretion, a particle in semen may be closer to the reproductive compartment, and a particle in a tumour or placenta may reflect the biology of that tissue as well as exposure.
The male findings are concerning but narrow. One set of studies detected polystyrene, polyvinyl chloride, polyethylene, and polypropylene in semen and urine. Higher concentrations of some polymers in semen were interpreted as possible evidence of accumulation toward the testes. The review also reports polymer-specific relationships with sperm outcomes: exposure to polytetrafluoroethylene was associated with lower sperm count, concentration, and motility, while PVC was specifically associated with impaired motility. These are reported associations in human studies, not a demonstration that any one polymer caused infertility. The studies may differ in how they measured exposure, and the presence of several polymers at once makes it difficult to isolate one particle from the rest of the exposure pattern.
The female findings show why the sample and outcome must stay attached. MNPs were reported in placenta and amniotic fluid, and one placental study found higher overall burdens and additional polymer types in pregnancies affected by impaired fetal growth. Another found a negative association between MNPs in amniotic fluid and gestational age. These observations raise a serious developmental question because the placenta and amniotic fluid are directly related to pregnancy. They do not tell us whether particles changed fetal growth, whether a pregnancy-related condition changed particle distribution, or whether another exposure influenced both.
Other reproductive samples point to disease-associated accumulation rather than a simple cause. The review describes polyethylene, polypropylene, and a polyethylene–polypropylene copolymer in cervical-cancer, uterine-fibroid, and myometrial samples. It also reports polystyrene, polyethylene, and PVC as more abundant in prostate tumours than in adjacent tissue. Tumours can have altered blood supply, rapid cell proliferation, and increased cellular uptake. Those features could passively concentrate circulating particles. A higher burden in a tumour therefore does not establish that the particles initiated the tumour.
There is also a useful null result. A study comparing people with endometriosis with controls found no difference in urinary MNP levels. That finding weakens the claim that urinary burden alone distinguishes the condition. It does not prove that MNPs have no possible role in endometriosis, because the study did not measure particles inside the ectopic lesions where the disease occurs. A negative result can be limited by the compartment chosen, the particles the method can detect, or the size of the study.